Anti-γ-Aminobutyric Acid Type β Receptor Antibody-Associated Encephalitis After 2 Cycles of Durvalumab Therapy in a Patient with Small Cell Lung Cancer: A Case Report

References

• Dutra LA, Abrantes F, Toso FF, Pedroso JL, Barsottini OGP, Hoftberger R. Autoimmune encephalitis: a review of diagnosis and treatment. Arq Neuropsiquiatr. 2018;76(1):41–49. doi:10.1590/0004-282x20170176
   PubMed Web of Science ®Google Scholar
• Armangue T, Leypoldt F, Dalmau J. Autoimmune encephalitis as differential diagnosis of infectious encephalitis. Curr Opin Neurol. 2014;27(3):361–368. doi:10.1097/WCO.0000000000000087
   PubMed Web of Science ®Google Scholar
• Zeng W, Cao L, Zheng J, Yu L. Clinical characteristics and long-term follow-up of seven cases of anti-GABABR encephalitis in patients of Han Chinese descent. Neurol Sci. 2020;41(2):373–378. doi:10.1007/s10072-019-04095-9
   PubMed Web of Science ®Google Scholar
• Lancaster E, Martinez-Hernandez E, Dalmau J. Encephalitis and antibodies to synaptic and neuronal cell surface proteins. Neurology. 2011;77(2):179–189. doi:10.1212/WNL.0b013e318224afde
   PubMed Web of Science ®Google Scholar
• Esposito S, Principi N, Calabresi P, Rigante D. An evolving redefinition of autoimmune encephalitis. Autoimmun Rev. 2019;18(2):155–163. doi:10.1016/j.autrev.2018.08.009
   PubMed Web of Science ®Google Scholar
• Yang S, Zhang Z, Wang Q. Emerging therapies for small cell lung cancer. J Hematol Oncol. 2019;12(1):47. PMID: 31046803; PMCID: PMC6498593. doi:10.1186/s13045-019-0736-3
   PubMed Web of Science ®Google Scholar
• Waqar SN, Morgensztern D. Treatment advances in small cell lung cancer (SCLC). Pharmacol Ther. 2017;180:16–23. PMID: 28579387. doi:10.1016/j.pharmthera.2017.06.002
   PubMed Web of Science ®Google Scholar
• Esposito G, Palumbo G, Carillio G, et al. Immunotherapy in small cell lung cancer. Cancers. 2020;12(9):2522. PMID: 32899891; PMCID: PMC7565004. doi:10.3390/cancers12092522
   PubMed Web of Science ®Google Scholar
• Onoi K, Chihara Y, Uchino J, et al. Immune checkpoint inhibitors for lung cancer treatment: a review. J Clin Med. 2020;9(5):1362. doi:10.3390/jcm9051362
   PubMed Web of Science ®Google Scholar
• Reynolds KL, Guidon AC. Diagnosis and management of immune checkpoint inhibitor-associated neurologic toxicity: illustrative case and review of the literature. Oncologist. 2019;24(4):435–443. doi:10.1634/theoncologist.2018-0359
   PubMed Web of Science ®Google Scholar
• Nakamura Y. Biomarkers for immune checkpoint inhibitor-mediated tumor response and adverse events. Front Med. 2019;6:119. doi:10.3389/fmed.2019.00119
   PubMed Web of Science ®Google Scholar
• Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol. 2017;8:49. doi:10.3389/fphar.2017.00049
   PubMed Web of Science ®Google Scholar
• Pan PC, Haggiagi A. Neurologic immune-related adverse events associated with immune checkpoint inhibition. Curr Oncol Rep. 2019;21(12):108. doi:10.1007/s11912-019-0859-2
   PubMed Web of Science ®Google Scholar
• Bien CG. Diagnosing autoimmune encephalitis based on clinical features and autoantibody findings. Expert Rev Clin Immunol. 2019;15(5):511–527. doi:10.1080/1744666X.2019.1573676
   PubMed Web of Science ®Google Scholar
• Newman MP, Blum S, Wong RC, et al. Autoimmune encephalitis. Intern Med J. 2016;46(2):148–157. doi:10.1111/imj.12974
   PubMed Web of Science ®Google Scholar
• Vogrig A, Joubert B, André-Obadia N, Gigli GL, Rheims S, Honnorat J. Seizure specificities in patients with antibody-mediated autoimmune encephalitis. Epilepsia. 2019;60(8):1508–1525. doi:10.1111/epi.16282
   PubMed Web of Science ®Google Scholar
• Nosadini M, Mohammad SS, Ramanathan S, Brilot F, Dale RC. Immune therapy in autoimmune encephalitis: a systematic review. Expert Rev Neurother. 2015;15(12):1391–1419. doi:10.1586/14737175.2015.1115720
   PubMed Web of Science ®Google Scholar
• Heine J, Prüss H, Bartsch T, Ploner CJ, Paul F, Finke C. Imaging of autoimmune encephalitis–relevance for clinical practice and hippocampal function. Neuroscience. 2015;309:68–83. doi:10.1016/j.neuroscience.2015.05.037
   PubMed Web of Science ®Google Scholar
• Tian Y, Gao A, Wen Q, et al. Immune-related neurological toxicities of PD-1/PD-L1 inhibitors in cancer patients: a systematic review and meta-analysis. Front Immunol. 2020;11:595655. doi:10.3389/fimmu.2020.595655
   PubMed Web of Science ®Google Scholar
• Barquín-García A, Molina-Cerrillo J, Garrido P, Garcia-Palos D, Carrato A, Alonso-Gordoa T. New oncologic emergencies: what is there to know about immunotherapy and its potential side effects? Eur J Intern Med. 2019;66:1–8. doi:10.1016/j.ejim.2019.05.020
   PubMed Web of Science ®Google Scholar
• Tison A, Quéré G, Misery L, et al. Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide, multicenter cohort study. Arthritis Rheumatol. 2019;71(12):2100–2111. doi:10.1002/art.41068
   PubMed Web of Science ®Google Scholar
• Choi J, Lee SY. Clinical characteristics and treatment of immune-related adverse events of immune checkpoint inhibitors. Immune Netw. 2020;20(1):e9. doi:10.4110/in.2020.20.e9
   PubMed Web of Science ®Google Scholar
• Hahn AW, Gill DM, Agarwal N, Maughan BL. PD-1 checkpoint inhibition: toxicities and management. Urol Oncol. 2017;35(12):701–707. doi:10.1016/j.urolonc.2017.08.005
   PubMed Web of Science ®Google Scholar
• Vogrig A, Muñiz-Castrillo S, Joubert B, et al. Central nervous system complications associated with immune checkpoint inhibitors. J Neurol Neurosurg Psychiatry. 2020;91(7):772–778. doi:10.1136/jnnp-2020-323055
   PubMed Web of Science ®Google Scholar
• Johnson DB, Manouchehri A, Haugh AM, et al. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J Immunother Cancer. 2019;7(1):134. doi:10.1186/s40425-019-0617-x
   PubMed Web of Science ®Google Scholar
• Shechtman Y, Shalata W, Khoury R, Mahajna A, Weller B, Agbarya A. Encephalitis induced by durvalumab during treatment of metastatic small-cell lung cancer: illustrative case and review of the literature. J Immunother. 2021;44(7):243–247. PMID: 33734140. doi:10.1097/CJI.0000000000000362
   PubMed Web of Science ®Google Scholar
• Zhao XH, Yang X, Liu XW, Wang SJ. Clinical features and outcomes of Chinese patients with anti-γ-aminobutyric acid B receptor encephalitis. Exp Ther Med. 2020;20(1):617–622. doi:10.3892/etm.2020.8684
   PubMed Web of Science ®Google Scholar